Nektar Therapeutics Data from REZOLVE-AD Study Accepted for Late-Breaking Oral Presentation

Nektar Therapeutics (NASDAQ:NKTR) is one of the hot stocks to buy with huge upside potential. On October 22, Nektar Therapeutics announced that new data from the ongoing REZOLVE-AD Phase 2b study of rezpegaldesleukin was accepted for a late-breaking oral abstract presentation. Rezpegaldesleukin is an IL-2 pathway agonist and regulatory T-cell/Treg proliferator being investigated for the treatment of atopic dermatitis.

The REZOLVE-AD Phase 2b study enrolled 393 patients with moderate-to-severe AD who had no prior treatment with biologic or JAK inhibitor therapies. Patients were enrolled across ~110 sites globally. The study’s primary endpoint is the mean improvement in EASI score at the end of the 16-week induction period.

Nektar Therapeutics Data from REZOLVE-AD Study Accepted for Late-Breaking Oral Presentation

Rezpegaldesleukin is a potential first-in-class resolution therapeutic wholly owned by Nektar Therapeutics, which is focused on addressing the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. The drug is a novel, first-in-class regulatory T cell stimulator being developed as a self-administered injection for multiple autoimmune and inflammatory conditions, including atopic dermatitis, which affects ~30 million people in the US.

Nektar Therapeutics is a biopharmaceutical company that discovers and develops therapies that selectively modulate the immune system to treat autoimmune disorders in the US and internationally.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

This article is originally published at Insider Monkey.